The Sudarshan Pharma Industries IPO date has been confirmed from March 9 and ended on March 14 .
The IPO of Sudarshan Pharma Industries is a book built issue worth Rs 50.10 crores. This issue consists of 68.62 lakh shares, all of which are fresh shares. The bidding for Sudarshan Pharma Industries IPO commenced on March 9, 2023, and concluded on March 14, 2023. The allotment for this IPO was finalized on Friday, March 17, 2023. Subsequently, the shares were listed on BSE SME on March 22, 2023.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
March 9 – 14 ,2023
Price Range
₹71 to ₹73 per share
Face Value
₹10 per share
GMP
₹5
Sudarshan Pharma Industries IPO GMP
The Sudarshan Pharma Industries IPO IPO GMP is ₹[ 5 ].
IPO Overview
Sudarshan Pharma sectors core business is to manufacture specialty chemicals and ingredients for the pharmaceutical, agrochemical, coating, paint, adhesive, and other sectors. SPIL is active in contract manufacturing, outsourcing, and supplying generic pharmaceutical formulations and medications to healthcare institutions, governments, non-governmental organizations (NGOs), and hospitals.
The IPO price range for Sudarshan Pharma Industries has been established at ₹71 to ₹73 per share. Retail investors are required to apply for a minimum lot size of 1600 shares, which translates to a minimum investment of ₹116,800. On the other hand, High Net Worth Individuals (HNIs) need to invest in 2 lots, equivalent to 3,200 shares, with a total amount of ₹233,600.
Sudarshan Pharma Industries IPO Date & Price Band Details
| IPO Date | March 9, 2023 to March 14, 2023 |
| Listing Date | March 22, 2023 |
| Face Value | ₹10 per share |
| Price Band | ₹71 to ₹73 per share |
| Lot Size | 1600 Shares |
| Total Issue Size | 6,862,400 shares (aggregating up to ₹50.10 Cr) |
| Fresh Issue | 6,862,400 shares (aggregating up to ₹50.10 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE SME |
| Market Maker portion | 344,000 shares |
Sudarshan Pharma Industries IPO Market Lot
The minimum requirement for investors to bid is 1600 shares, and they can bid in multiples of this amount. The table below illustrates the minimum and maximum investment that retail investors and HNI can make in terms of shares and the corresponding amount.
| Application | Lot Size | Shares | Amount |
| Retail (Min) | 1 | 1600 | ₹116,800 |
| Retail (Max) | 1 | 1600 | ₹116,800 |
| HNI (Min) | 2 | 3,200 | ₹233,600 |
Sudarshan Pharma Industries IPO Allotment and Listing Dates
| IPO Open Date | Thursday, March 9, 2023 |
| IPO Close Date | Tuesday, March 14, 2023 |
| Basis of Allotment | Friday, March 17, 2023 |
| Initiation of Refunds | Monday, March 20, 2023 |
| Credit of Shares to Demat | Tuesday, March 21, 2023 |
| Listing Date | Wednesday, March 22, 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on March 14, 2023 |
Sudarshan Pharma Industries Company Financials
| Parameters | Period Ending on September 30, 2022 (₹ Lakhs) | Year ending on 31st March, 2022 (₹ Lakhs) | Year ending on 31st March, 2021 (₹ Lakhs) |
| Revenue from operation | 19,589.87 | 35,709.46 | 19,335.03 |
| Profit After Tax | 360.70 | 530.37 | 267.12 |
| EBITDA | NA | 1,143.57 | 754.24 |
| EBITDA Margin | NA | NA | NA |
| EPS (Basic) | NA | 3.43 | 1.75 |
| Period Ended | Year ending on As on 31st March, 2022 | Year ending on As on 31st March, 2021 | Year ending on As on 31st March, 2020 |
| Current Asset | 12,958.00 | 8,764.35 | 4,688.21 |
| Current Liabilities | 10,104.01 | 7,122.17 | 3,433.90 |
Company Profile
SPIL, a Mumbai-based company, was established in 2008 and specializes in contract manufacturing of generic formulations. In addition to this, the company is involved in import and export activities, as well as the supply of specialty chemicals, API, and Intermediates. To meet the specific requirements of their clients, SPIL outsources their manufacturing facility from suppliers both in India and abroad. The company’s generic products find applications in various industries such as paint, food, pharma, and adhesive. They also provide contract manufacturing, supply, and outsourcing services for medicines and
pharma formulations to hospitals, NGOs, government organizations, and healthcare institutes. With a portfolio of 50 pharma formulations, SPIL supplies them under their own brand name in the form of tablets, ointments, capsules, and injectables. To ensure effective marketing of their pharmaceutical formulations and products, SPIL has established its own sales force and distribution network in 5 states. This enables them to cater to both the Indian and international markets. Additionally, the company offers formulation development and quality control services, providing customized solutions to their clients.
Registrar Info
| Name | Kfin Technologies Limited |
| Phone number | 04067162222, 04079611000 |
| Email ID | einward.ris@kfintech.com |
| Website | https://kosmic.kfintech.com/ipostatus/ |
Contact Details
| Name | Sudarshan Pharma Industries |
| Phone number | 022- 42221111 |
| Email ID | compliance@sudarshanpharma.com |
| Website | https://www.sudarshanpharma.com/ |
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
